title: [Tocolysis in preterm labour--current recommendations].
abstract: Common use of tocolytic drugs in preterm labor has not been shown to reduce the rate of neonatal mortality and morbidity Currently tocolytics should be administered in the course of a 48-h administration of antepartum glucocorticoids and/or transfer of the gravida to a center with neonatal intensive care unit. Only oxytocin receptor antagonist--atosiban and short-acting beta-agonists--fenoterol are licensed to reduce preterm uterine activity Owing to its safety and efficacy atosiban should be the first-choice tocolytic, especially in women with other diseases or multiple gestations.
authors.forename: Mirosław
authors.initials: M
authors.lastname: Wielgoś
authors.forename: Dorota A
authors.initials: DA
authors.lastname: Bomba-Opoń
mesh_terms: D000318:Adrenergic beta-Agonists / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D005280:Fenoterol / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007752:Obstetric Labor, Premature / Q000188:drug therapy* / Q000517:prevention & control; D017410:Practice Guidelines as Topic; D011247:Pregnancy; D011256:Pregnancy Outcome; D015145:Tocolysis / Q000009:adverse effects / Q000379:methods* / Q000592:standards*; D015149:Tocolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D014590:Uterine Contraction / Q000187:drug effects; D014668:Vasotocin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D000318:Adrenergic beta-Agonists; D015149:Tocolytic Agents; C047046:atosiban; D005280:Fenoterol; D014668:Vasotocin